The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was $3.70 for the day, down -6.33% from the previous closing price of $3.95. In other words, the price has decreased by -$6.33 from its previous closing price. On the day, 1.06 million shares were traded. ZNTL stock price reached its highest trading level at $4.01 during the session, while it also had its lowest trading level at $3.69.
Ratios:
Our analysis of ZNTL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.19 and its Current Ratio is at 9.19. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on June 20, 2024, Downgraded its rating to Neutral and sets its target price to $5 from $28 previously.
Wedbush Downgraded its Neutral to Underperform on June 18, 2024, whereas the target price for the stock was revised from $15 to $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 31 ’24 when Gallagher Cam sold 9,597 shares for $11.98 per share. The transaction valued at 114,972 led to the insider holds 633,680 shares of the business.
HAUSMAN DIANA sold 3,356 shares of ZNTL for $42,353 on May 09 ’24. The Chief Medical Officer now owns 373,876 shares after completing the transaction at $12.62 per share. On Feb 12 ’24, another insider, Epperly Melissa B,, who serves as the Chief Financial Officer of the company, sold 2,573 shares for $11.44 each. As a result, the insider received 29,435 and left with 451,449 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 262748848 and an Enterprise Value of -180880032. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.48 while its Price-to-Book (P/B) ratio in mrq is 0.57. Its current Enterprise Value per Revenue stands at -4.46 whereas that against EBITDA is 0.872.
Stock Price History:
Over the past 52 weeks, ZNTL has reached a high of $29.03, while it has fallen to a 52-week low of $3.27. The 50-Day Moving Average of the stock is -55.42%, while the 200-Day Moving Average is calculated to be -70.56%.
Shares Statistics:
ZNTL traded an average of 1.42M shares per day over the past three months and 1311830 shares per day over the past ten days. A total of 70.77M shares are outstanding, with a floating share count of 62.14M. Insiders hold about 12.49% of the company’s shares, while institutions hold 113.61% stake in the company. Shares short for ZNTL as of 1719532800 were 9618824 with a Short Ratio of 6.76, compared to 1717113600 on 17514952. Therefore, it implies a Short% of Shares Outstanding of 9618824 and a Short% of Float of 27.37.
